Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | IDH2 | P48735 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099647 | 0.89 | ALDH1A1 (0.92) | ALDH1A1TAAR1IDH2USP2GAA | |
| SCHEMBL14264138 | 0.89 | ALDH1A1 (1.00) | ALDH1A1TAAR1IDH2USP2GAA | |
| SCHEMBL11936604 | 0.83 | MAPT (0.63) | ALDH1A1TAAR1GAAKCNH3MEN1 | |
| SCHEMBL115405 | 0.83 | MAPT (0.57) | ALDH1A1TAAR1USP2GAAKCNH3 | |
| SCHEMBL14869409 | 0.81 | ALDH1A1 (0.77) | ALDH1A1TAAR1IDH2USP2GAA | |
| SCHEMBL2735960 | 0.81 | CA1 (0.56) | ALDH1A1TAAR1CA1CA2CA9 | |
| SCHEMBL28184867 | 0.80 | ALDH1A1 (0.75) | ALDH1A1TAAR1IDH2USP2GAA | |
| SCHEMBL20000094 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TAAR1KCNH3MAPTNFKB1 | |
| SCHEMBL14869433 | 0.77 | GAA (0.62) | ALDH1A1GAACA1CA2CA9 | |
| SCHEMBL4569978 | 0.77 | LMNA (0.71) | ALDH1A1IDH2GAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-27 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8188273-B2 | Insecticidal (1,3,5)-triazinyl phenyl hydrazones | DOW AGROSCIENCES, LLC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120040837-A1 | INSECTICIDAL (1,3,5)-TRIAZINYL PHENYL HYDRAZONES | DOW AGROSCIENCES LLC (US) | 2012-02-16 | — | — | US | disclosed |
| US-8067588-B2 | Insecticidal (1,3,5)-triazinyl phenyl hydrazones | DOW AGROSCIENCES LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090093481-A1 | INSECTICIDAL (1,3,5)-TRIAZINYL PHENYL HYDRAZONES | DOW AGROSCIENCES LLC (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093481-A1 | INSECTICIDAL (1,3,5)-TRIAZINYL PHENYL HYDRAZONES | HELZ, API5, CRYZ | ALDH1A1 1530/4885TAAR1 2144/4885IDH2 1076/4885 |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | ALDH1A1 1040/4885TAAR1 3026/4885IDH2 166/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
| US-20120040837-A1 | INSECTICIDAL (1,3,5)-TRIAZINYL PHENYL HYDRAZONES | HELZ, API5, CRYZ | ALDH1A1 1530/4885TAAR1 2144/4885IDH2 1076/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | ALDH1A1 1040/4885TAAR1 3026/4885IDH2 166/4885 |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALDH1A1 980/4885TAAR1 2974/4885IDH2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.